GlaxoSmithKline: EU expands approval for COPD drug
(CercleFinance.com) - GlaxoSmithKline on Friday said European regulators approved expanded use of its once-daily inhaler Trelegy Ellipta to include patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) that is not adequately treated with dual bronchodilation.
The label update is based on data from a study that showed that Trelegy Ellipta was superior to other treatments in patients with moderate-to-severe COPD, improving lung function and (health-related) quality of life.
While bronchodilation is recognised as the core COPD therapy, many patients continue to struggle with symptoms and exacerbations over time.
Trelegy Ellipta, which is developed with US partner Innoviva, was originally approved in the European Union in November 2017 as a maintenance treatment for COPD.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The label update is based on data from a study that showed that Trelegy Ellipta was superior to other treatments in patients with moderate-to-severe COPD, improving lung function and (health-related) quality of life.
While bronchodilation is recognised as the core COPD therapy, many patients continue to struggle with symptoms and exacerbations over time.
Trelegy Ellipta, which is developed with US partner Innoviva, was originally approved in the European Union in November 2017 as a maintenance treatment for COPD.
Copyright (c) 2018 CercleFinance.com. All rights reserved.